Fidelion Diagnostics Partnership: BioNexus Gene Lab Corp. Secures Exclusive Southeast Asian Rights for VitaGuard™ and 15% Equity Stake

BioNexus Gene Lab Corp. completed a strategic investment in Fidelion Diagnostics, acquiring a 15% equity stake in the AI-oncology platform and securing exclusive rights to VitaGuard™ across Southeast Asia. The deal positions BGLC for long-term growth in precision oncology adoption in the region. The transaction was structured to maximize balance-sheet strength and minimize dilution, with a dual-asset value creation model combining a commercial asset and an investment asset.